Related Experiment Video
Updated: Oct 3, 2025
08:56
A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
11.1K
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Li-Juan Deng1, Wei-Qing Deng1,2, Shu-Ran Fan2
1Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Molecular Cancer
|February 15, 2022
Summary
Abnormal N6-methyladenosine (m6A) modification is linked to cancer. This review explores traditional medicines and AI for discovering new m6A-targeting anticancer drugs.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Aberrant N6-methyladenosine (m6A) modification is implicated in cancer development, progression, and prognosis.
- m6A regulators are emerging as novel targets for anticancer drug development.
Purpose of the Study:
- To review the latest findings on m6A modification in cancer.
- To summarize sources for discovering m6A-targeted anticancer agents.
- To highlight the potential of artificial intelligence (AI) in this drug discovery process.
Main Methods:
- Literature review of m6A modification in cancer.
- Analysis of traditional medicine resources for m6A-targeting compounds.
- Exploration of computer-based chemosynthetic compound discovery.
- Discussion of AI-assisted drug discovery approaches.
Main Results:
- m6A modification plays critical roles in various stages of cancer progression.
- Traditional medicines and synthetic compounds offer rational sources for m6A-targeting agents.
- AI presents a promising avenue for accelerating the discovery of m6A-targeting anticancer drugs.
Conclusions:
- m6A-targeting agents hold significant potential for cancer treatment.
- A multi-stage approach, including traditional medicine, chemical synthesis, and AI, can advance m6A-targeted drug discovery.
Related Concept Videos
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:15Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:10Drugs that Destabilize Microtubules
2.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:23Abnormal Proliferation
4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K